BNTX
BioNTech SE · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 760.71K | $74.78M | n/a | −1 |
| Q2 2026 | 92 | 0 | 32.20M | $3.00B | +8 | −10 |
| Q1 2026 | 95 | +4 | 29.16M | $2.59B | +13 | −9 |
| Q4 2025 | 91 | +4 | 29.39M | $2.80B | +4 | n/a |
| Q3 2025 | 13 | +1 | 23.37M | $2.30B | +1 | n/a |
| Q2 2025 | 9 | -3 | 22.65M | $2.41B | +1 | −4 |
| Q1 2025 | 10 | -2 | 14.39M | $1.31B | n/a | −2 |
| Q4 2024 | 12 | -1 | 14.53M | $1.66B | +1 | −2 |
| Q3 2024 | 12 | +1 | 13.93M | $1.65B | +3 | −2 |
| Q2 2024 | 11 | n/a | 15.47M | $1.24B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 8.28M | n/a | $665.08M | 0.5% | n/c | 1 | SEC ↗ ×4 |
| 2 | PRIMECAP Management ✦ | 4.79M | n/a | $384.89M | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Capital World Investors ✦ | 955.98K | n/a | $76.82M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 654.12K | n/a | $52.56M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 461.71K | n/a | $37.10M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 101.50K | n/a | $8.16M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 68.55K | n/a | $5.51M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 66.21K | n/a | $5.32M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 52.20K | n/a | $4.20M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 35.98K | n/a | $2.89M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 11.65K | n/a | $936,435 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 272 holders, 47.28M shares, $3.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, 10% owner · 36.21K sh · $3.45M
Officer, 10% owner · 27.00K sh · $2.49M
Officer, 10% owner · 24.00K sh · $2.30M
Officer, 10% owner · 21.00K sh · $2.03M
Officer, 10% owner · 72.00K sh · $7.00M
Officer, 10% owner · 17.00K sh · $1.64M
Officer, 10% owner · 17.00K sh · $1.66M
Officer, 10% owner · 32.00K sh · $3.14M
Officer, 10% owner · 34.00K sh · $3.34M
Officer, 10% owner · 34.00K sh · $3.35M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology